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Abstract
Background: The human β-defensins (hBDs) are a highly conserved family of cationic antimicrobial and
immunomodulatory peptides expressed primarily by epithelial cells in response to invasion by bacteria, fungi and
some viruses. To date, the most studied members of this family of peptides are hBD-1, -2, and −3. Expression of
hBD-1 and −2 has been demonstrated previously in cultured microglia and astrocytes of both mouse and human
brain. Unlike inducible hBD-2 and −3, hBD-1 is constitutively expressed and is not generally upregulated by
proinflammatory factors. In this study, we investigated whether hBDs, as active components of the innate immune
response, are affected by pathological events in the Alzheimer’s disease (AD) brain. We assessed the expression of
hBD-1, -2, and −3 in tissue obtained at autopsy from AD and age-matched control brains.
Methods: Fixed and frozen choroid plexus and the CA1 region of the hippocampus were obtained at autopsy from
individuals diagnosed with AD, or from age-matched control brains without diagnosed neurodegenerative disease.
Histopathologically diagnosed AD brain tissue was obtained for our study. Immunocytochemical analysis was
performed using affinity purified polyclonal antibodies directed against hBD-1, -2, or −3. TaqMan gene expression
assays were used to quantify the mRNA of hBD-1, -2, and −3 in the choroid plexus and hippocampus.
Immunocytochemical detection of iron deposits was achieved using a modified Perl’s stain for redox-active iron.
In vitro experiments were performed on human primary oral epithelial cells to model the human choroid plexus
epithelial response to ferric chloride. Cells were then exposed to ferric chloride added to selected wells at 0, 1, or
10 mM concentrations for 24 h at 37°C. Total mRNA was isolated to quantify hBD-1 mRNA expression by RTqPCR.
Results: hBD-1 peptide is apparent in astrocytes of the AD hippocampus and hippocampal neurons, notably within
granulovacuolar degeneration structures (GVD). A higher level of hBD-1 was also seen in the choroid plexus of AD
brain in comparison to age-matched control tissue. Increased expression of hBD-1 mRNA was observed only in the
choroid plexus of the AD brain when compared to expression level in age-matched control brain. Redox-active iron
was also elevated in the AD choroid plexus and in vitro addition of Fe+3Cl3 to cultured epithelial cells induced
hBD-1 mRNA expression.
(Continued on next page)
* Correspondence: wmw5@case.edu; xiong.wei.zhu@case.edu
1Department of Biological Sciences, School of Dental Medicine, Case Western
Reserve University, 2124 Cornell Rd., Cleveland, OH 44106, USA
2Department of Pathology, School of Medicine, Case Western Reserve
University, 10900 Euclid Ave., Cleveland, OH 44106, USA
Full list of author information is available at the end of the article
JOURNAL OF 
NEUROINFLAMMATION
© 2013 Williams et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Williams et al. Journal of Neuroinflammation 2013, 10:127
http://www.jneuroinflammation.com/content/10/1/127
(Continued from previous page)
Conclusions: Our findings suggest interplay between hBD-1 and neuroimmunological responses in AD, marked by
microglial and astrocytic activation, and increased expression of the peptide within the choroid plexus and
accumulation within GVD. As a constitutively expressed component of the innate immune system, we propose that
hBD-1 may be of considerable importance early in the disease process. We also demonstrate that increased iron
deposition in AD may contribute to the elevated expression of hBD-1 within the choroid plexus. These findings
represent a potentially important etiological aspect of Alzheimer’s disease neuropathology not previously reported.
Keywords: Alzheimer’s, Antimicrobial, Brain, Choroid plexus, Defensin, Granulovacuolar, Immunomodulatory,
Inflammation
Background
Mammalian β-defensins are an evolutionarily conserved
group of cationic, non-glycosylated antimicrobial and
immunomodulatory peptides that are expressed in all
mammals, including humans [1,2]. Constitutively ex-
pressed human β-defensin-1 and inducible β-defensin-2
(hBD-1 and −2, respectively) are commonly expressed
by epithelial cells, and are important contributors to in-
nate host defense [3,4]. These peptides have the poten-
tial to act as activators and modulators of adaptive
immunity within astrocytes and microglia, brain cells
critical to the cerebral neuroinflammatory response,
as both cell types have been shown to express hBD-1
and −2 in vitro [5-9]. These findings were confirmed
by Nakayama et al. who also reported constitutive ex-
pression of hBD-1 in the human choroid plexus (CP)
[10]. The CP, composed principally of epithelium,
endothelium and stroma, is strategically located be-
tween the peripheral circulation and cerebral ventricles,
and actively participates in regulation of reciprocal im-
mune functions between the brain and peripheral cir-
culation. Direct involvement of the CP in Alzheimer’s
disease (AD) neuropathology is well documented with
overt epithelial cell atrophy and thickening of epithe-
lial basement membrane with concomitant impairment
of synthetic, secretory, and transporter functions,
including reduced clearance of amyloid-β [11-14]. In
addition to secretion of cerebrospinal fluid (CSF),
which is reduced in AD [15], the CP acts as a primary
immunosurveillance and defense mechanism against in-
vading pathogens and systemic diseases [16]. The CP is
a principal regulator of the intracerebral immune re-
sponse and inflammation, as indicated by the presence
of mast cells, macrophages, granulocytes, and immuno-
competent cells within the tissue [17,18]. Other im-
mune alterations specific to AD, including pseudolinear
deposits of IgG and deposits of C1q associated with
IgM, suggestive of an autoimmune origin have been
reported [19]. The cause or causes underlying patho-
logical changes and dysfunction within the CP remain
equivocal, although it is apparent that oxidative stress-
induced modification of proteins, unrelated to presence
of fibrillar amyloid-β, contributes to CP pathology in
AD. These modifications include glycation end-
products carboxymethyl-lysine and N-carboxyethyl-
lysine within the CP of AD brain [20]. The studies
cited above suggest CP dysfunction is a likely contribu-
tor to neuropathological and inflammatory sequelae in
the AD brain.
In this study, we evaluated the expression of hBDs
within the AD brain and accumulation of redox-active
iron within the CP epithelium. We show that the expres-
sion of hBD-1 mRNA is significantly elevated in the
Alzheimer’s choroid plexus and the protein is apparent
in neurons of the hippocampus. Further, granulovacuolar
degeneration (GVD) is found to be a specific site of
hBD-1 peptide localization. GVD are small cytoplasmic
granules that are increased in neurons of the AD brain;
proteins previously described in GVD represent the au-
tophagic ubiquitin-proteasome system, unfolded protein
response, endosomal and lysosomal proteins, and tau
and amyloid processing events, as well as stress-
activated and mitogen-activated protein induction
[21-27]. The GVD may play a role similar to that of
stress granules, structures that form following various
stressors including heat shock, oxidative stress, and, of
relevance to this study, infection [28]. The present study
provides evidence for GVD formation reflecting a
neuroprotective response and suggests that redox-active
iron may contribute to alteration of the inflammatory
process by upregulating expression of hBD-1, a principal
component of the innate host defense system.
In AD, morphological changes and increased immu-
nological responses in the CP contribute to decreased
CSF synthesis and secretion, and increased oxidative
stress [29]. Despite highly controlled homeostatic iron
levels within the healthy brain [30], redox-active iron
accumulates in the AD brain [31,32] with a con-
centration appearing to correlate with the severity of
cognitive deficit [33]. Our findings suggest that ele-
vated iron levels in the AD CP, and perhaps also
within hippocampal regions, contribute to the increase
in hBD-1 expression and an altered innate immune
response.




Brain tissue histopathologically diagnosed with AD using
multiple criteria (‘definite’ AD by CERAD criteria [34],
Braak Stage V-VI [35], and ‘high likelihood AD’ by NIA-
Reagan criteria [36]), as well as age-matched control
brain tissue, were used for our study. Specifically, fixed
and frozen CP from AD patients (n = 8) and age-
matched controls (n = 7) was obtained from the NICHD
Brain and Tissue Bank for Developmental Disorders at
the University of Maryland, Baltimore, MD, USA. All tis-
sue samples were obtained within 2 to 12 hours post-
mortem with similar ages between groups ranging from
66 to 89 years of age. Additionally, fixed and frozen
samples of hippocampus were obtained from Case
Western Reserve University and University Hospitals of
Cleveland, according to approved Institutional Review
Board protocols. Samples from control cases (n = 8, ages
74–91) and neuropathologically confirmed AD cases
(n = 11, ages 72–94) were used for PCR experiments.
For immunocytochemistry, AD cases (n = 9, ages 59–91,
mean = 80.1 years) and control (n = 5, ages 53–101,
mean = 72.2 years) were analyzed. Skin samples from 3
cases were also collected post-mortem for use as a positive
control tissue. Fixed tissues were embedded in paraffin and
used for immunocytochemical analysis. Antigen affinity
purified polyclonal antibodies directed against hBD-1 (Cat #
P25350), -2 (Cat # P161G50), and −3 (Cat # P24150) were
purchased from PeproTech (Rocky Hill, NJ, USA).
These primary antibodies were produced from rabbit
(hBD-1 and −3) or goat sera (hBD-2) pre-immunized
with >98% pure recombinant defensin peptide. Anti-
bodies were subsequently purified by affinity chroma-
tography using the respective immobilized defensin
peptide matrix (PeproTech). TaqMan gene expression
assays were purchased from Applied Biosystems (Life
Technologies, Carlsbad, CA, USA).
RTqPCR
Total RNA was extracted from frozen brain tissue by
homogenization in TRI reagent (Ambion, Life Technolo-
gies, Carlsbad, CA, USA) and further purified using an
RNeasy Mini Kit from Qiagen (Valencia, CA, USA), as
instructed by the manufacturer. The purified RNA was
treated with Turbo DNase (Ambion) to remove trace DNA.
RNA was converted to cDNA using the RETROScript
RT-qPCR kit (Ambion), according to the manufacturer’s
instructions. Briefly, the purified total RNA (100 ng) was re-
verse transcribed with cloned Moloney murine leukemia
virus reverse transcriptase (5 U) by incubating at 44°C for
60 min, followed by heating at 92°C for 10 min. RT-qPCR
using TaqMan gene specific assays with context sequence
(GGCCTCAGGTGGTAACTTTCTCACA) was performed
in triplicate on cDNA samples in 96-well optical plates on
an ABI StepOne Plus Thermocycler (Applied Biosystems).
For each 20 μL TaqMan reaction, 2 μL cDNA was mixed
with 10 μL 2× TaqMan Fast Universal PCR Master Mix
(Applied Biosystems) and 1 μL of 20× TaqMan Assay Mix.
Standard fast PCR parameters were used.
Data was normalized to glyceraldehyde dehydrogenase
(GAPDH) and shown as the relative RQ value. This stable
reference gene was selected by testing AD and age-
matched control brain samples on a TaqMan Human En-
dogenous Control Plate (Applied BiosystemsWMicroAmpW
Life Technologies, Carlsbad, CA, USA). The data indicated
five stable genes that could be used for normalization.
Using the geNORM (PrimerDesign) algorithm, the best
choice for normalization of RT-qPCR data from AD vs.
age-matched control brain samples was a combination of
two genes, human acidic ribosomal protein (huPO) and hu-
man β2-microglobulin (huβ2m). Stability of huGAPDH was
second only to that of huβ2m/huPO out of a total of 11
suggested reference genes.
Immunocytochemical analysis
Paraffin was removed from tissue sections with two changes
of xylene; tissue sections were then hydrated through de-
scending concentrations of ethanol to Tris buffered saline
(TBS, 50 mM Tris, 150 mM NaCl, pH = 7.6). Endogenous
peroxidase activity was ablated by 30 min incubation in 3%
hydrogen peroxide in methanol. Antigen retrieval using cit-
rate buffer (pH 6) in a pressure cooker (Biocare Medical,
Concord, CA, USA) was performed. Non-specific antibody
binding sites were blocked with a 30 minute incubation in
10% normal goat serum (NGS) in TBS, and sections incu-
bated overnight in primary antibody diluted in 1% NGS
in TBS at 4°C. Secondary antibodies were applied
followed by PAP complex and staining developed with 3’-
3’-diaminobenzidine (Dako North America, Carpenteria,
CA, USA). Sections were dehydrated and mounted with
Permount mounting medium.
To verify the presence of hBD-1 peptide in glial cells,
double label immunocytochemistry was performed on hip-
pocampal sections from either AD or non-AD brain using
rabbit polyclonal antibody to hBD-1 (PeproTech) detected
using the PAP method with brown reaction product DAB
and with mouse monoclonal antibody to glial fibrillary
acidic protein (GFAP, clone GA5, Millipore), detected with
the alkaline phosphatase anti-alkaline phosphatase method
using Fast Blue as chromogen. Stained sections were
mounted with Crystalmount, coverslipped and imaged
using Zeiss Axiocam mounted on a Zeiss Axiophot (Carl
Zeiss Microscopy, LLC, Thornwood, NY, USA). Epidermal
sections of human skin known to express hBD-1 were also
subjected to hBD-1 antibody as a positive control.
Immunocytochemical detection of iron deposits within
the CP and hippocampus was achieved by a modified
Perl’s stain for redox-active iron using 7% potassium
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ferrocyanide in 3% HCl [30,31]. The CP epithelial cell
layer was identified using an affinity purified rabbit poly-
clonal antibody (ABBiotec, San Diago, CA, USA) to
transthyretin, a marker for CP epithelial cells.
Cell culture of human primary epithelial cells and
exposure to redox-active iron
Primary oral epithelial cells were used to model the re-
sponse of CP epithelial cells to redox-active iron (Fe+3).
Cells were obtained from human donors according to
the policies described by the Institutional Review Board
at Case Western Reserve University. After informed con-
sent by selected patients oral epithelial cells were
extracted from healthy oral tissue overlying impacted
third molars, as described by Oda and Watson [37]. In
brief, cells were cultured in EpiLife growth medium
(Cascade Biologists, Portland, OR, USA) and maintained
under 5% CO2 at 37°C. Primary cells were grown as a
monolayer under serum-free conditions. Upon reaching
confluence, cells from at least three donors were
trypsinized, detached, and pooled before reseeding in
EpiLife growth medium at 4 × 104 cells/well in 6-well
culture plates. Before challenging with dilutions of ferric
chloride, cells were incubated under 5% CO2 at 37°C,
and cultured until ~80–95% confluence (~3 × 105 cells/
well). Ferric chloride at 1 and 10 mM was added to se-
lected wells and cells were incubated for an additional
24 h. Experiments were terminated by aspiration of the
incubation medium and addition of TRIzol reagent (Life
Technologies, Grand Island, NY, USA) to each well for
subsequent quantitation of hBD-1 mRNA by RT-qPCR.
Statistical analysis
Data are presented as the Mean ± S.E. Statistical analysis
was performed using exact probabilities for the non-
parametric Mann Whitney ‘U’ test where N1 = 7, N2 = 8
(CP), or N1 = 8, N2 = 11 (hippocampus).
Results
Beta defensin-1 peptide is increased in hippocampus and
CP of the AD brain
Examination of hippocampal sections revealed the ap-
parent accumulation of hBD-1 peptide in the cytoplasm
of pyramidal neurons in only 1 out of 5 age-matched
Figure 1 Immunocytochemical demonstration of hBD-1 in the hippocampus. Age-matched controls (A,B) vs. AD (C,D) shows an elevated
protein expression in the cytoplasm of pyramidal neurons in AD compared to non-AD control brain. The expected localization of hBD-1 in glial
cells was also demonstrated in AD cases (C, inset). In AD cases, GVD is also specifically stained (D, arrows). In D, inset shows a higher
magnification image of the GVD-containing neuron marked with an asterisk (*). Scale bar A–D = 50 μm; Insets C,D = 20 μm.
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control cases (Figure 1A,B) versus 8 out of 9 AD cases
(Figure 1C,D). The hBD-1 peptide was also tentatively
identified in astrocytes of the AD brain (Figure 1C,
inset), an expected finding since hBD-1 expression has
been reported in cultured human astrocytes. Most strik-
ing was the strong and specific staining of GVD within
pyramidal neurons of AD hippocampus (Figure 1D ar-
rows, and inset).
The CP epithelial cell layer from age-matched control
brain was clearly delineated by the presence of
transthyretin (Figure 2A). Within the CP, the hBD-1
peptide was detected only in epithelial cells, consistent
with presence of intracellular hBD-1. We noted weak ex-
pression of the peptide in non-AD age-matched CP
(Figure 2B), but a strong, distinct signal in the CP epi-
thelium from AD brain (Figure 2C). We could not detect
hBD-2 or −3 peptide in either CP or hippocampal tissue
sections derived from either AD or control brain (data
not shown).
In Figure 3A we show the presence of hBD-1 peptide
in glial cells expressing GFAP, a glial cell marker. Human
skin used as a positive control for the presence of hBD-1
shows high expression of the peptide in the upper epi-
dermal layer (Figure 3B).
Expression of hBD-1 mRNA is elevated in CP epithelium,
but not in hippocampal cells of the AD brain
Using RT-qPCR we assessed the expression of hBD-1, -2,
and −3 mRNAs in both the hippocampus and CP from AD
brains and age-matched controls. Expression of hBD-1
mRNA is significantly elevated in the AD CP in compari-
son to age-matched controls (*P = 0.02, Figure 4A). How-
ever, the levels of hBD-1 mRNA were similar in both AD
and control hippocampus (Figure 4B). Expression of mRNA
for hBD-2 and −3 was not detected in either CP or hippo-
campus from AD or control brains (data not shown).
Redox-active iron deposition occurs in CP epithelial cells
of the AD brain
Using a modification of the Perl’s stain to specifically de-
tect Fe+3, a redox-active form of non-heme iron, we vi-
sualized a strong signal within the CP epithelium of the
AD cases, but not in epithelium of the control CP
(Figure 5).
Redox-active iron upregulates in vitro expression of hBD-
1 in human epithelial cells
The 24 h exposure of cultured human primary epithelial
cells to either 1 or 10 mM Fe+3Cl3 induced a detectable
Figure 2 Transthyretin is a marker protein for epithelial cells. Epithelial cells of the choroid plexus (CP) are demonstrated in an age-matched
control brain using antibody to transthyretin (A). While hBD-1 is only weakly expressed in control CP epithelium (B), the peptide is strongly
expressed by these cells in the AD CP (C).
Figure 3 hBD-1 is apparent in astroglial cells of the hippocampus. The expected localization of hBD-1 brown reaction product in glial cells
was demonstrated in AD cases by colocalization with an antibody to GFAP (blue) (A, inset). Arrows mark the numerous glial cells containing both
GFAP and hBD-1, while arrowheads denote neurons containing only the brown hBD-1 reaction product. Specificity of the antibody and method
used for detection of hBD-1 was tested on tissue sections of human epidermal skin cells, known to express hBD-1, as a positive control (B). Scale
bar (inset) = 50 μm.
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dose-dependent upregulation of hBD-1 mRNA (n = 3,
U = 0, P = 0.014) relative to untreated control cells
(Figure 6).
Discussion
The hBD gene cluster is located in chromosome 8p22-
23, a region containing multiple genes related to innate
immunity and the nervous system [38]. With the excep-
tion of constitutively expressed hBD-1, inducible hBD-2
and −3 are generally upregulated by an inflammatory en-
vironment [39,40]. Thus, surprisingly, we detected the
upregulated expression of hBD-1, which is generally un-
responsive to inflammation. Conversely, we failed to de-
tect expression of hBD-2 or hBD-3, despite the reported
presence of neuroinflammation in affected regions of the
AD brain, including the hippocampus and CP [41,42].
The hBD-1 gene (DEFB1) is a single copy gene with
several SNPs that have been associated with the patho-
genesis of some chronic inflammatory diseases, inclu-
ding asthma and chronic obstructive pulmonary disease
[43,44]. Genomic variations in DEFB1 also contribute to
the clinical course of severe sepsis and inflammation
with presence of specific haplotypes associated with ei-
ther increased susceptibility to, or protection from, se-
vere infection and fatal outcome [45]. This latter study
underscores a possible role for hBD-1 in modulating in-
flammation within the CNS and suggests that the ob-
served elevation in hBD-1 expression within the AD
brain is a protective response to an inflammatory envir-
onment. One obvious question is whether susceptibility
to inflammation within the CNS is influenced by specific
genomic variants of DEFB1, and whether individuals
with AD express a gene variant that is less effective in
modulating inflammation.
hBD-1 is the only known hBD that is constitutively
expressed and is rarely upregulated [46-48]. The peptide is
not only immunomodulatory through chemotaxis of mem-
ory T lymphocytes and stimulation to maturity of imma-
ture myeloid dendritic cells [49,50], but responsive and
cytotoxic to gram-negative bacteria and adenovirus. Expres-
sion of hBD-1 is not significantly affected by exposure to
LPS, Salmonella Dublin, or Escherichia coli [51]. This study
is the first to report the effect of a neurodegenerative dis-
ease on expression of a well characterized antimicrobial
and immunomodulatory peptide. Here, we show significant
elevation of the hBD-1 peptide and mRNA level in CP epi-
thelium, and increased peptide in hippocampal neurons of
the AD brain relative to age-matched control brain tissues.
The underlying cause(s) of increased hBD-1 expression
in the AD brain is not apparent. It is also unclear
whether the hBD-1 peptide could be functioning as an
antimicrobial, immunomodulator or both, and whether
functionality of the peptide affects clinical symptoms of
AD. We thus propose several mechanisms that might
explain our results based upon our own recent findings,
and the published studies of others.
The presence of hBD-1 within the CP, an interface be-
tween brain parenchyma and the systemic circulation, sug-
gests that increased expression in the AD brain CP could
be a response to microbial-derived stimuli impinging from
the systemic side of the blood-CSF barrier. Influenza, Sen-
dai and Herpes simplex viruses are known to modulate
hBD-1 expression [52], and Herpes simplex DNA has been
shown to localize quite specifically to the amyloid plaques
of the AD brain [53]. To date though, identification of
pathogenic determinants in AD, including bacteria, viruses
and fungi has been an inconsistent finding, and no single
pathogenic agent has been categorically identified as a con-
tributor to AD neuropathology or cognitive decline [54].
Nonetheless, the functional role that hBD-1 plays within
the CP could be influenced by pathogenic stimuli, such as
non-self-pattern recognition associated with AD.
Figure 4 hBD-1 expression is increased in the AD CP epithelium. hBD-1 mRNA expression in the CP epithelium from AD brain (n = 8) shows
a statistically significant (*P = 0.02) elevation in peptide expression, compared to age-matched control tissue (n = 7) (A). Results are expressed as
the mean ± S.E. No statistically significant difference in hBD-1 mRNA expression was found between the hippocampus from AD brain (n = 11)
compared to age-matched controls (n = 8) (B).
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Another intriguing mechanism that could underlie
changes in hBD-1 expression within the CNS is a non-
inflammatory upregulation of the peptide by altered
biological clock control of peptide expression through
c-myc. Sherman et al. [55] have shown that albumin can
upregulate expression of hBD-1 in HCT-116 cells con-
comitant with elevation of c-myc, a response that was
inhibited by addition of a c-myc inhibitor. Additional
studies showed that the 5 kbp promoter region of the
defensin peptide contains putative binding sites (E-box-
like sequences) for c-myc that are binding sites for the
dimerized transcription factors CLOCK and BMAL1
[55,56]; noteworthy is that components of the innate im-
mune system are regulated by the biological clock
[57,58]. Thus, hBD-1 expression level may conform to
influence from the biological clock and binding of c-myc
to the defensin promoter region [51]. This mechanism
may be quite relevant to hBD expression in AD in view
of the altered circadian rhythm of the master clock cells
in the superchiasmatic nucleus of the AD brain [59]. Al-
though alterations in biological clock function occur in
both aging and AD, the circadian disturbance appears to
be more pronounced in the AD brain [60].
It is possible that the observed increase in hBD-1 within
the CP and hippocampus occurs by different mechanisms.
We believe that the increased presence of hBD-1 within
neurons may represent an acute neuroprotective response
of the brain to extra- or intra-cerebral factors. Presence of
hBD-1 within GVD, structures which can function as
autophagosomes [61] but also show both morphological
and protein-based similarities to stress granules [28], may
signal a neuronal response to induction of cellular stress
by a chronic, proinflammatory environment. Since the
majority of neurons containing GVD are not yet undergo-
ing neurodegeneration, i.e., they lack hyperphosphorylated
tau, neurofibrillary pathology, and are not apoptotic,
the apparent elevation of hBD-1 in these structures
could help identify the cellular response to stress.
Additional study of mild cognitive impairment, in-
cluding cases with mild AD, is necessary to clarify
the role of glial activation known to occur early on in
the disease process [62].
Figure 5 Immunocytochemical demonstration of redox-active iron deposits within the CP epithelium of the AD brain. Redox-active iron
deposits are not detectable in the CP of age-matched control brain. Redox-active iron was detected using a modified Perl’s stain [30].
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An increase in hBD-1 peptide in the hippocampus of
the AD brain without a respective increase in mRNA
would not be without precedent. In fact, attempts to
correlate protein levels with similar changes in mRNA
expression have met with mixed results [63]. The in-
crease in hBD-1 peptide in the AD hippocampus may
reflect upregulation of a post-translational pathway such
as that described by Acquaviva et al. [64] to explain their
observed increase in the frataxin protein without an
associated increase in expressed mRNA. The lack of an
increase in mRNA expression, corresponding to an in-
crease in protein level is not an infrequent occurrence as
is demonstrated by a study on new molecular targets for
the anticancer drug, rapamycin [65]. In this study, out of
56 yeast proteins increased in abundance following ex-
posure to rapamycin, 26 did so without a detectable
change in mRNA expression. It is also possible that ac-
cumulation of the hBD-1 peptide in the GVD may occur
over years and derive from glial cell death and release of
hBD-1 peptide that subsequently is sequestered via the
hypothesized protective function of neuronal GVD.
Borenstein et al. [66] proposed a similar hypothesis to ex-
plain the presence of defensin peptides (NP-1, -2, and −5)
in infected rabbit testis. These defensins are expressed by
macrophages and neutrophils, but both these cell-types
were absent from the tissue samples in which the defensins
were detected. Similarly, Sahasrabudhe et al. [67] noted in-
creased expression of hBD-1 in inflamed human salivary
gland ducts, but without a corresponding increase in hBD-
1 mRNA. In their study, detectable levels of the peptide
were demonstrated by immunoblot. Unfortunately, we
could not verify the presence of this small (3.9 kDa) peptide
by Western blot of hippocampal tissue. We attribute this to
a peptide concentration in the brain that is below the level
of detectability for our antibody. It cannot be completely
rules out that our antibody is cross-reacting with another
protein; however, we believe this to be unlikely, given that
there is no cross-reactivity between our antibody to hBD-1
and other beta-defensins having close homology to hBD-1
(PeproTech, personal communication). Nevertheless, with-
out quantitative verification that our antibody is, in fact,
detecting hBD-1 in the hippocampus we make the tentative
assertion that hBD-1 is present and its expression
upregulated in the AD hippocampus.
Redox-active iron insidiously accumulates within the
ageing brain, but the rate of accumulation is accelerated
in several neurodegenerative diseases, including AD
[68,69]. Accumulation occurs primarily in regions of the
brain that show susceptibility to AD neuropathology
[70]. Of particular interest is the underlying cause of
hBD-1 upregulation within the epithelium of the AD CP
where we also observed increased sequestering of redox-
active iron. We are unaware of any histological verifica-
tion of abnormal iron accumulation specifically within
the CP epithelium. Iron levels within the CNS are largely
regulated by the blood-CSF and blood–brain barriers
[71,72]. Dysregulation of iron homeostasis with resulting
increase of redox-active iron is a probable contributor to
AD neuropathology and inflammation through the pro-
motion of oxidative conditions [73]. We propose that
the elevated level of redox-active iron within the CP epi-
thelium underlies our observed increase in hBD-1. This
proposal is supported by the demonstrated role of iron
as a regulator of immune function and our findings from
the present study showing that iron can induce the
upregulation of hBD-1 in cultured epithelium (Figure 6).
Furthermore, Lee et al. [74] have shown that both cellu-
lar iron deficiency and overload can modulate elements
of the innate and adaptive immune response, including
the upregulated expression of the chemotactic cytokine
Figure 6 Redox-active iron increases hBD-1 expression in epithelial cells in vitro. hBD-1 mRNA expression in human epithelium grown in
culture subjected to sham-exposure or exposed to 1 or 10 mM Fe+3Cl3 during a 24 h incubation at 37°C. Results are expressed as the mean ± S.D.
of 3 independent experiments (*P = 0.014).
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MIP3α/CCL20. As a constitutively expressed antimicrobial/
immunomodulatory peptide, hBD-1 expression would be
expected to respond to signals impinging upon the epithe-
lium indicative of pathogen infection. Our demonstrated
ability to upregulate hBD-1 mRNA expression in vitro
through exposure of epithelial cells to redox-active ferric
iron (Fe+3Cl3) but not ferrous iron (data not shown), sug-
gests that redox-active iron underlies upregulated expres-
sion of hBD-1, perhaps through activation of cellular
pathways and innate immune defenses normally up-
regulated by intracellular invasion of iron-containing patho-
gens [75]. In fact, both iron depletion and iron overload
have been shown to alter patterns of cellular gene expres-
sion [76]. As an interface between the systemic circulation
and CSF, the CP epithelium undoubtedly plays a critical
role in regulating iron metabolism and therefore iron avail-
ability to pathogens attempting to invade the CNS [77]. We
suggest that the increased presence of intracellular iron
within the CP, regardless of the underlying cause, contrib-
utes to the upregulation of the hBD-1 peptide and possibly
other components of the innate immune response by the
CP epithelium.
Modulation of the innate and adaptive immune response
in the CNS is an intricate process likely involving the hBD-
1 peptide. Recently, Cribbs et al. [78] showed extensive
upregulation of innate immune system pathways in post
mortem hippocampus and cortex from aged and AD-
afflicted individuals relative to these same regions from
young (20 to 59 years) cases. Our observed increase in
hBD-1, a component of the innate immune system, within
the AD brain is therefore consistent with this observed acti-
vation of innate immune pathways and underscores the
need for further study of hBD-1 function and possible con-
tribution of genomic variation in the DEFB1 gene to
neuroinflammation in AD. Absence of detectable hBD-2
or −3 in either AD or age-matched control brains suggests
hBD-1 may have a unique influence on innate immune re-
sponse within the brain. However, future studies will re-
quire additional comparisons to young adult brain in order
to accurately assess hBD function.
The possibility that hBD-1 may function as an antimicro-
bial or immuno-modulating element in neuroinflammation
is supported by the literature cited above and by the novel
findings presented in this study. The role or roles that spe-
cific antimicrobial peptides, such as hBD-1, may play in
neurodegenerative diseases, including AD, requires further
investigation in order to clarify their contributions to the
overall host immune response in these diseases.
Conclusions
Our study results suggest the expression of the human anti-
microbial peptide hBD-1 is elevated in the CP and hippo-
campus of the AD brain, relative to hBD-1 levels in the
brain of non-demented, age-matched controls. This
increased expression localized to the CP, an interface be-
tween the brain and systemic circulation, and the apparent
increase in the neuronal cell bodies and glia within the
hippocampus, suggest an active role for hBD-1 as a poten-
tial modulator of the host innate immune response within
the CNS.
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